Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Status:
Not yet recruiting
Trial end date:
2023-04-24
Target enrollment:
Participant gender:
Summary
This study is an open-label, multicenter Phase II study of capivasertib administered orally
in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL).